ZEO ScientifiX (OTCQB: ZEOX) Advances to Semi-Finals in \$101 Million XPRIZE Healthspan Competition

Company Poised for Major Clinical Milestone in Regenerative Biologics

Key Highlights

• ZEO ScientifiX, Inc. (OTCQB: ZEOX) has been selected as a Qualified Team advancing to the Semi-Finals stage of the XPRIZE Healthspan competition, a high-profile, \$101 million global contest aimed at fundamentally extending human healthspan.
• The XPRIZE Healthspan initiative seeks therapeutics capable of restoring muscle, cognitive, and immune function by at least 10 years—ideally 20 years—in people aged 65-80, within a one-year timeframe.
• ZEO’s selection follows rigorous review by XPRIZE Healthspan judges. The company is now preparing its Finals Application, aiming for the next round and a potential win in this globally recognized challenge.
• The company’s technology platform centers on regenerative biologics—specifically extracellular vesicle (exosome) therapeutics and next-generation delivery systems designed to target the biological mechanisms of aging and inflammation.
• ZEO operates advanced laboratory facilities within the Center for Collaborative Research at Nova Southeastern University, Florida’s largest private research university.

Strategic Scientific and Clinical Leadership

ZEO has assembled a world-class, multidisciplinary team to advance its Finals Application and clinical strategy, including recognized leaders in medicine, gene therapy, telomere biology, regenerative medicine, and clinical trial execution:

• Dr. George C. Shapiro, MD, FACC: Chief Medical Officer, board-certified in Internal Medicine and Cardiovascular Disease, with over 35 years of clinical experience and a track record as principal investigator on multiple FDA-regulated studies.
• Elizabeth Parrish: Founder and CEO of BioViva, pioneering human gene therapy in telomerase and longevity pathways.
• Dr. Bill Andrews, PhD: Renowned authority in telomere biology and cellular aging, credited for significant advances in telomerase activation.
• Dr. Brian Kennedy, PhD: Former CEO of the Buck Institute for Research on Aging, currently leading the Healthy Longevity Translational Research Programme at the National University of Singapore.
• Dr. Marilyn Glassberg, MD: Professor and Chair at Loyola University Chicago, expert in pulmonary fibrosis and regenerative medicine.
• Dr. Sharon J. Elliot, PhD: Professor at Loyola University Chicago, specializing in exosome cargo biology and regenerative signaling.
• Dr. Michael Bellio, PhD: VP of Research & Manufacturing at ZEO, published expert in extracellular vesicle and stem cell biology.
• Dr. David Karli, MD: Harvard-trained physician, with extensive experience in advanced regenerative technologies and clinical data analysis.
• Dr. Daniel Rothenstein, PhD: Director of Biostatistics at Pluri Biotech, with over 20 years in FDA-regulated clinical trial design.
• Lior Raviv: Chief Technology Officer of Pluri Inc., specializing in GMP process development and clinical-grade production of cell-based therapies.

Clinical and Commercial Implications

• In the Semi-Finals, ZEO aims to advance its therapeutic platform into controlled human clinical evaluation, generating key data on safety, biological activity, and functional outcomes in muscle, cognition, and immune function.
• Positive results could pave the way for pivotal clinical trials, regulatory submissions, and commercialization opportunities, directly aligning with XPRIZE Healthspan’s ambitious objectives.
• This news follows ZEO’s recent appointment as the official regenerative medicine educational partner for the American Academy of Anti-Aging Medicine (A4M), further cementing its leadership in this high-growth field.

About ZEO ScientifiX, Inc.

ZEO ScientifiX, Inc. (OTCQB: ZEOX) is a clinical-stage, SEC-reporting biopharmaceutical company specializing in regenerative biologics. The company leverages state-of-the-art research at Nova Southeastern University’s Center of Collaborative Research to develop scalable, clinically actionable therapies targeting aging and inflammation.

For more information, visit https://zeoscientifix.com.

Potential Shareholder Impact

• This advancement in the XPRIZE Healthspan competition is a significant milestone that could materially benefit ZEOX’s valuation and investor sentiment if the company progresses through the finals or secures a prize.
• Success in generating positive clinical data or winning the XPRIZE could unlock new funding, partnership, and market opportunities, directly impacting share value.
• However, investors should note that there are inherent uncertainties, including the company’s ability to advance in the competition, complete its finals application, meet objectives, and secure necessary funding. These factors may cause significant volatility in the share price.

About XPRIZE

XPRIZE is a recognized global leader in large-scale innovation competitions, with a 30-year track record of accelerating solutions to humanity’s greatest challenges. More at xprize.org.

Contact

ZEO ScientifiX, Inc.
Karlista Maroney, Director of Growth Strategy
[email protected]

Disclaimer: This article contains forward-looking statements subject to risks and uncertainties, including but not limited to the outcome of the XPRIZE Healthspan competition, clinical trial results, and regulatory approvals. Investors should perform their own due diligence and consult financial advisors before making investment decisions. The author and publisher assume no responsibility for investment actions taken based on this information.

View Zeo ScientifiX, Inc. Historical chart here